BIO-MEDICAL MATERIALS AND ENGINEERING, published by IOS PRESS, serves as a vital platform for advancing the fields of biomaterials and biomedical engineering. With its ISSN 0959-2989 and E-ISSN 1878-3619, the journal has been consistently disseminating high-quality research since its inception in 1991, covering a diverse range of studies on the development and application of biomedical materials. Although currently classified in the Q4 quartile in several categories including biomaterials and biomedical engineering, the journal aims to appeal to a broad audience of researchers and professionals, fostering collaboration and innovation in translating new materials into clinical practice. Located in the Netherlands, it emphasizes the importance of interdisciplinary approaches and provides a forum for new ideas and findings that could significantly impact healthcare solutions. While not an open-access journal, it provides various access options to maximize the reach and engagement of its research. Researchers, practitioners, and students alike will find valuable insights and comprehensive studies within its pages, contributing to the continued evolution of biomedical sciences.

The International Journal of Biomaterials, published by HINDAWI LTD, is a premier platform for disseminating groundbreaking research in the fields of biomaterials and biomedical engineering. With an Open Access approach since 2009, this journal provides unhindered access to innovative studies and applications aimed at advancing medical technologies and improving patient outcomes. Notably ranked in the Q3 category for both Biomaterials and Biomedical Engineering in 2023, it serves as an essential resource for researchers, practitioners, and students alike. The journal's Scopus rankings, including a 49th percentile in Biomedical Engineering and a 40th percentile in Biomaterials, further underscore its growing prominence in the academic community. With contributions spanning from 2011 to 2024, the journal seeks to foster collaborative research and promote developments that enhance the understanding and application of biomaterials in healthcare.

JOURNAL OF BIOMATERIALS APPLICATIONS, published by SAGE PUBLICATIONS LTD, serves as a pivotal platform for the dissemination of cutting-edge research in the field of biomaterials and biomedical engineering. With an ISSN of 0885-3282 and an E-ISSN of 1530-8022, this journal has been a respected venue for scholarly communication since its inception in 1986. Aiming to provide comprehensive insights into the applications of biomaterials, this journal publishes high-quality articles that explore innovative materials and methodologies, thereby fostering advancements in medical technology and tissue engineering. The journal consistently ranks in the third quartile (Q3) for both Biomaterials and Biomedical Engineering categories, strengthening its position among the noteworthy academic resources available today. With a dedicated readership comprising researchers, industry professionals, and students, JOURNAL OF BIOMATERIALS APPLICATIONS plays a vital role in supporting knowledge exchange and scientific progress within these dynamic fields.

Nature Biomedical Engineering is a premier journal published by NATURE PORTFOLIO, focusing on innovative research at the intersection of engineering and biomedical sciences. With an ISSN of 2157-846X, this journal aims to disseminate groundbreaking studies that advance the field of bioengineering, biotechnology, and medical applications. Since its inception in 2017, it has rapidly earned a reputation for excellence, consistently achieving a Q1 ranking in various categories including Bioengineering and Biomedical Engineering, and receiving acclaim in prestigious Scopus rankings, boasting top positions in the fields of Computer Science Applications and Medicine. The journal operates under a rigorous peer-review process, ensuring that all published articles contribute substantially to the existing body of knowledge. Furthermore, it facilitates a broad accessibility model for researchers and practitioners, bolstering collaboration and innovation within the global scientific community. Nature Biomedical Engineering is not just a publication; it serves as a vital platform for thought leadership in the transformative field of biomedical engineering.

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

Tissue Engineering Part C: Methods is a prestigious academic journal published by MARY ANN LIEBERT, INC, specializing in the dynamic and rapidly evolving fields of bioengineering and biomedical engineering. With an ISSN of 1937-3384 and E-ISSN 1937-3392, this journal provides a platform for the dissemination of cutting-edge research from 2008 to 2024, showcasing methodologies that advance the science of tissue engineering. Ranked in the second and third quartiles across several categories in 2023, including a notable Q2 in Biomedical Engineering, the journal is recognized for its contributions to the interface of biology and engineering. Additionally, it holds commendable Scopus ranks that highlight its influence and reach within the scientific community. Although it does not offer open access, the journal remains vital for researchers, professionals, and students seeking insightful articles that bridge the gap between theoretical research and practical application in tissues and regenerative medicine. With its rigorous peer-review process and commitment to quality, Tissue Engineering Part C: Methods continues to be an essential resource for those at the forefront of tissue engineering innovations.

Materials Science & Engineering C-Materials for Biological Applications is a premier journal published by ELSEVIER, dedicated to advancing the field of biomaterials through interdisciplinary research. With a robust ISSN of 0928-4931, this journal has made its mark in the realms of Chemical Engineering and Materials Science, achieving impressive Scopus rankings within its categories, namely Rank #16/151 in Bioengineering (89th percentile) and Rank #13/112 in Biomaterials (88th percentile). Although the journal's coverage in Scopus has been discontinued since 2021, it remains a critical resource for researchers, professionals, and students eager to explore innovative materials and their applications in biological contexts. The journal’s open access policy enhances its accessibility, fostering a global exchange of knowledge and inspiring future advancements in the field of materials science.

Progress in Biomaterials is a premier journal published by Springer Heidelberg, dedicated to advancing the field of biomaterials through the dissemination of high-quality research articles, reviews, and case studies. The journal, with an ISSN of 2194-0509 and an E-ISSN of 2194-0517, holds an esteemed position within both the Biomaterials and Chemical Engineering fields, as evidenced by its rankings in the Q2 and Q1 quartiles, respectively. With its convergence over the years from 2013 to 2023, it has maintained a strong impact on scientific discourse, ranking #15 in Chemical Engineering and #30 in Biomaterials according to Scopus metrics. The journal is based in Heidelberg, Germany, and aims to provide an open platform for interdisciplinary collaboration amongst researchers, professionals, and students alike, fostering innovation and progress in biomaterials research. As a crucial resource for those engaged in this dynamic field, it empowers authors and readers to explore the latest trends, technologies, and applications in biomaterials development.

Acta Biomaterialia, published by Elsevier Science Ltd, is a leading journal in the fields of biochemistry, biomaterials, biomedical engineering, biotechnology, and molecular biology. With an ISSN of 1742-7061 and an E-ISSN of 1878-7568, this prestigious journal has secured a remarkable position in the academic community, evidenced by its inclusion in the Q1 category across multiple disciplines for 2023. It ranks impressively at #21 in biochemistry, #16 in biomedical engineering, #18 in biotechnology, and #11 in biomaterials, reflecting its high impact and relevance to ongoing research and development. The journal provides a platform for disseminating innovative research and advancements in the design and application of biomaterials, contributing to scientific discussions that propel the field forward. Although it does not currently offer open access options, Acta Biomaterialia continues to attract contributions that advance our understanding of biomaterials and their interactions with biological systems, ensuring that researchers, professionals, and students remain informed about the latest trends and breakthroughs in this rapidly evolving area of study.

Bioengineering-Basel, an esteemed journal published by MDPI, stands at the forefront of innovation in the field of bioengineering since its inception in 2014. With an E-ISSN of 2306-5354, this fully Open Access journal based in Switzerland provides a platform for researchers and professionals to disseminate cutting-edge findings across various aspects of bioengineering, including biomaterials, tissue engineering, and biopharmaceuticals. The journal has been recognized with a Q3 ranking in the 2023 Bioengineering category, reflecting its commitment to quality and relevance. By facilitating widespread accessibility to academic knowledge, Bioengineering-Basel aims to foster collaboration and stimulate thought leadership within the global research community, making it an indispensable resource for students, scholars, and industry practitioners alike.